Clinical trials: Vehicle, completed
Knee Arthroscopy, Acute Pain
"Comparison of Intra-articular of 0.2% Ropivacaine vs. 0.75% Ropivacaine in Postoperative of Knee Arthroscopy"
All patients with acute lesions that attend the orthopedic and trauma center of the ABC medical center are invited to participate in the study.
- Trial name
- ropivacaine (NCT05807945)
- Testing
- Ropivacaine 0.75% Injectable Solution, Ropivacaine 0.2% Injectable Solution
- Where
- Mexico
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Paola M Zamora Munoz
Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis
This study will evaluate the efficacy and safety of two concentrations (0.3 percent [%] and 1%) of twice daily LNK01004 ointment for the topical treatment in adult subjects with atopic dermatitis.
- Trial name
- NCT07071610
- Testing
- LNK01004 ointment 0.3%, LNK01004 ointment 1.0%, Vehicle
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Atopic Conjunctivitis
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye).
- Trial name
- NCT00884585
- Testing
- Cyclosporine Vehicle, Cyclosporine 0.010%
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 176 people
- Sponsor
- Allergan
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Plaque Psoriasis
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT01882647
- Testing
- 000-0551 Lotion, Vehicle Lotion
- Where
- 11 sites in United States
- Volunteers
- 222 people
- Sponsor
- Therapeutics, Inc.
Androgenetic Alopecia
Photosensitization Study in Androgenetic Alopecia
This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)
- Trial name
- NCT02791243
- Testing
- Finasteride 0.25%, Negative Control
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Polichem S.A.
Visible Light Exposure on Healthy Back Skin
ANTIPIGMENTING OR DEPIMENTING EFFICACY UNDER PART OF VISIBLE LIGHT
The study intends to validate a protocol and define a positive reference to evaluate the efficacy of anti-pigmenting and depigmenting agents under part of visible Light exposures, between 400nm to 450nm.
- Trial name
- ACR_BIOVI_21-0 (NCT06945393)
- Testing
- Cosmetic topical products
- Where
- Romania
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- L'Oreal
Actinic Keratosis
Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions
A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple Actinic Keratosis Lesions
- Trial name
- NCT01583816
- Testing
- Resiquimod 0.03%, Resiquimod 0.01%
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 218 people
- Sponsor
- Spirig Pharma Ltd.
Moderate to Severe Dry Eye Syndrome
Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome
- Trial name
- NCT00814515
- Testing
- NOVA22007 (Ciclosporin 0.1%), NOVA22007
- Where
- France
- Volunteers
- 482 people
- Sponsor
- Santen SAS
Molluscum Contagiosum
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
- Trial name
- NCT03436615
- Testing
- SB206 4%, SB206 8%, SB206 12%
- Where
- 18 sites in United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Novan, Inc.
Lymphoma, B-Cell, Lymphoma, Non-hodgkins
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Background: The immune system fights infection and can affect cancer cells. T cells are white blood cells that are a major part of the immune system. T cells can destroy tumors.
- Trial name
- NCT02659943
- Testing
- Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Acne, Acne Scars
Topical Icariin on Acne and Acne Scars
The goal of this clinical trial is to examine whether topical application of icariin can improve acne and atrophic acne scars in adults.
- Trial name
- NCT07076784
- Testing
- Icariin, Vehicle Control
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Seoul National University Hospital
Allergic Conjunctivitis
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial with Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic…
- Trial name
- NCT03660878
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Vulvovaginal Atrophy
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.
- Trial name
- NCT01845649
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 57 sites in United States
- Volunteers
- 550 people
- Sponsor
- Warner Chilcott
Breast Cancer, Cognitive Change
Computerized Cognitive Training in Breast Cancer Survivors
For millions of cancer survivors, cognitive impairment is a prevalent, severe, and persistent problem that is associated with other symptoms (depressive symptoms, anxiety and fatigue), poorer work ability, and poorer quality of…
- Conditions
- Breast Cancer, Cognitive Change, Cognitive Impairment, Quality of Life
- Trial name
- NCT05570604
- Testing
- Sweep Seeker, Bird Safari, Jewel Diver
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Ohio State University
Acne Vulgaris
A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne
This is a 12 week, multi-site, double-blind, vehicle-controlled study in subjects with mild to moderate facial acne. Subjects will be randomized 1:1 to apply either topical NAG or vehicle gel daily.
- Trial name
- NCT02404285
- Testing
- Next Science Acne Gel, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 68 people
- Sponsor
- Next Science TM
Active, Symptomatic Blepharitis
Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of subjects with active, symptomatic Blepharitis.
- Trial name
- ISV-305 (NCT01543490)
- Testing
- ISV-305, Vehicle
- Where
- United States
- Volunteers
- 558 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Meibomian Gland Dysfunction, MGD-Meibomian Gland Dysfunction
Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction
To evaluate the efficacy and safety of two strengths of HY02 Ointment versus Vehicle administered twice daily for twelve weeks in subjects with a diagnosis of Inflamed Meibomian Gland Dysfunction.
- Trial name
- NCT03888378
- Testing
- 0.3% Topical Minocycline Ointment, 1% Topical Minocycline Ointment, Topical Vehicle Ointment
- Where
- 20 sites in United States
- Volunteers
- 270 people
- Sponsor
- Hovione Scientia Limited
Actinic Keratoses
Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses
This study was to be conducted as a multi-centre, randomized, investigator-blinded, active and vehicle-controlled, intra-individual (split-face/scalp) non-inferiority (regarding efficacy) and superiority (regarding pain) study.
- Trial name
- COMET2 (NCT01821391)
- Testing
- NDL-PDT, c-PDT
- Where
- 18 sites in France, Germany and 3 more
- Volunteers
- 131 people
- Sponsor
- Galderma R&D
Motor Vehicle Injury, Safety Issues
Safety-Enhancing Motor Vehicle Child Safety Seat
This study aims to assess the usability of a load leg design for caregivers who must install the child safety seat into a vehicle.
- Trial name
- NCT06384989
- Testing
- Child restraint system with load leg feature
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Minnesota HealthSolutions
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.